Novo allocates as much as $2 billion for acquisitions

10/30/2008 | Bloomberg

Novo Nordisk is setting aside as much as $2 billion to fund potential takeovers of biotech firms in the coming 12 months, Chief Financial Officer Jesper Brandgaard announced. Of particular interest to the Danish drugmaker are companies specializing in diabetes and inflammatory disorders, Brandgaard said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations